Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 363

1.

Protein kinase D displays intrinsic Tyr autophosphorylation activity: insights into mechanism and regulation.

Cobbaut M, Derua R, Parker PJ, Waelkens E, Janssens V, Van Lint J.

FEBS Lett. 2018 Jun 22. doi: 10.1002/1873-3468.13171. [Epub ahead of print]

PMID:
29933512
2.

Protein Kinase C-β Dictates B Cell Fate by Regulating Mitochondrial Remodeling, Metabolic Reprogramming, and Heme Biosynthesis.

Tsui C, Martinez-Martin N, Gaya M, Maldonado P, Llorian M, Legrave NM, Rossi M, MacRae JI, Cameron AJ, Parker PJ, Leitges M, Bruckbauer A, Batista FD.

Immunity. 2018 Jun 19;48(6):1144-1159.e5. doi: 10.1016/j.immuni.2018.04.031. Epub 2018 Jun 5.

3.

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.

Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, Martin-Fernandez ML, Cameron A, Fraternali F, Ng T, Parker PJ.

Elife. 2018 May 1;7. pii: e32271. doi: 10.7554/eLife.32271.

4.

Protein kinase N1 critically regulates cerebellar development and long-term function.

zur Nedden S, Eith R, Schwarzer C, Zanetti L, Seitter H, Fresser F, Koschak A, Cameron AJ, Parker PJ, Baier G, Baier-Bitterlich G.

J Clin Invest. 2018 May 1;128(5):2076-2088. doi: 10.1172/JCI96165. Epub 2018 Apr 16.

5.

Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma.

Miles J, Applebee CJ, Leboucher P, Lopez-Fernandez S, Lee DJ, Guarch R, Ward S, Parker PJ, López JI, Larijani B.

BBA Clin. 2017 Oct 13;8:97-102. doi: 10.1016/j.bbacli.2017.10.002. eCollection 2017 Dec.

6.

Uncoupling TORC2 from AGC kinases inhibits tumour growth.

Cameron AJM, Veeriah S, Marshall JJT, Murray ER, Larijani B, Parker PJ.

Oncotarget. 2017 Aug 9;8(49):84685-84696. doi: 10.18632/oncotarget.20086. eCollection 2017 Oct 17.

7.

Loss of Protein Kinase Novel 1 (PKN1) is associated with mild systolic and diastolic contractile dysfunction, increased phospholamban Thr17 phosphorylation, and exacerbated ischaemia-reperfusion injury.

Francois AA, Obasanjo-Blackshire K, Clark JE, Boguslavskyi A, Holt MR, Parker PJ, Marber MS, Heads RJ.

Cardiovasc Res. 2018 Jan 1;114(1):138-157. doi: 10.1093/cvr/cvx206.

8.

PKCε Controls Mitotic Progression by Regulating Centrosome Migration and Mitotic Spindle Assembly.

Martini S, Soliman T, Gobbi G, Mirandola P, Carubbi C, Masselli E, Pozzi G, Parker PJ, Vitale M.

Mol Cancer Res. 2018 Jan;16(1):3-15. doi: 10.1158/1541-7786.MCR-17-0244. Epub 2017 Oct 11.

9.

Working Memory Capacity and Surgical Performance While Exposed to Mild Hypoxic Hypoxemia.

Parker PJ, Manley AJ, Shand R, O'Hara JP, Mellor A.

Aerosp Med Hum Perform. 2017 Oct 1;88(10):918-923. doi: 10.3357/AMHP.4761.2017.

PMID:
28923140
10.

One hundred years on: Ypres and ATLS.

Parker RS, Parker PJ.

Emerg Med J. 2017 Nov;34(11):766-767. doi: 10.1136/emermed-2017-207023. Epub 2017 Sep 4. No abstract available.

PMID:
28870995
11.

Non-battle injury among repatriated UK armed forces since cessation of combat operations: a prospective observational study.

Toman E, Beaven A, Naumann DN, Myatt RW, Parker PJ, Kay AR.

J R Army Med Corps. 2018 Feb;164(1):19-24. doi: 10.1136/jramc-2017-000766. Epub 2017 Aug 23.

PMID:
28835512
12.

PKCɛ switches Aurora B specificity to exit the abscission checkpoint.

Pike T, Brownlow N, Kjaer S, Carlton J, Parker PJ.

Nat Commun. 2016 Dec 22;7:13853. doi: 10.1038/ncomms13853.

13.

EGFR oligomerization organizes kinase-active dimers into competent signalling platforms.

Needham SR, Roberts SK, Arkhipov A, Mysore VP, Tynan CJ, Zanetti-Domingues LC, Kim ET, Losasso V, Korovesis D, Hirsch M, Rolfe DJ, Clarke DT, Winn MD, Lajevardipour A, Clayton AH, Pike LJ, Perani M, Parker PJ, Shan Y, Shaw DE, Martin-Fernandez ML.

Nat Commun. 2016 Oct 31;7:13307. doi: 10.1038/ncomms13307.

14.

aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization.

Soriano EV, Ivanova ME, Fletcher G, Riou P, Knowles PP, Barnouin K, Purkiss A, Kostelecky B, Saiu P, Linch M, Elbediwy A, Kjær S, O'Reilly N, Snijders AP, Parker PJ, Thompson BJ, McDonald NQ.

Dev Cell. 2016 Aug 22;38(4):384-98. doi: 10.1016/j.devcel.2016.07.018.

15.

Corrigendum: Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.

Barrow-McGee R, Kishi N, Joffre C, Ménard L, Hervieu A, Bakhouche BA, Noval AJ, Mai A, Guzmán C, Robbez-Masson L, Iturrioz X, Hulit J, Brennan CH, Hart IR, Parker PJ, Ivaska J, Kermorgant S.

Nat Commun. 2016 Jul 22;7:12392. doi: 10.1038/ncomms12392. No abstract available.

16.

Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes.

Barrow-McGee R, Kishi N, Joffre C, Ménard L, Hervieu A, Bakhouche BA, Noval AJ, Mai A, Guzmán C, Robert-Masson L, Iturrioz X, Hulit J, Brennan CH, Hart IR, Parker PJ, Ivaska J, Kermorgant S.

Nat Commun. 2016 Jun 23;7:11942. doi: 10.1038/ncomms11942.

17.

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer.

Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A.

PLoS Biol. 2016 Mar 7;14(3):e1002414. doi: 10.1371/journal.pbio.1002414. eCollection 2016 Mar. No abstract available.

18.

PP2A binds to the LIM domains of lipoma-preferred partner through its PR130/B″ subunit to regulate cell adhesion and migration.

Janssens V, Zwaenepoel K, Rossé C, Petit MM, Goris J, Parker PJ.

J Cell Sci. 2016 Apr 15;129(8):1605-18. doi: 10.1242/jcs.175778. Epub 2016 Mar 4.

19.

Knockout of the PKN Family of Rho Effector Kinases Reveals a Non-redundant Role for PKN2 in Developmental Mesoderm Expansion.

Quétier I, Marshall JJT, Spencer-Dene B, Lachmann S, Casamassima A, Franco C, Escuin S, Worrall JT, Baskaran P, Rajeeve V, Howell M, Copp AJ, Stamp G, Rosewell I, Cutillas P, Gerhardt H, Parker PJ, Cameron AJM.

Cell Rep. 2016 Jan 26;14(3):440-448. doi: 10.1016/j.celrep.2015.12.049. Epub 2016 Jan 7.

20.

The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers.

Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan AM, Burns MB, McDougle RM, Parker PJ, Brown WL, Harris RS.

Cancer Res. 2015 Nov 1;75(21):4538-47. doi: 10.1158/0008-5472.CAN-15-2171-T. Epub 2015 Sep 29.

21.

Functional proteomic biomarkers in cancer.

Larijani B, Perani M, Alburai'si K, Parker PJ.

Ann N Y Acad Sci. 2015 Jun;1346(1):1-6. doi: 10.1111/nyas.12749. Epub 2015 Mar 19.

PMID:
25801208
22.

Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM.

Coban O, Zanetti-Dominguez LC, Matthews DR, Rolfe DJ, Weitsman G, Barber PR, Barbeau J, Devauges V, Kampmeier F, Winn M, Vojnovic B, Parker PJ, Lidke KA, Lidke DS, Ameer-Beg SM, Martin-Fernandez ML, Ng T.

Biophys J. 2015 Mar 10;108(5):1013-26. doi: 10.1016/j.bpj.2015.01.005.

23.

Mitotic catenation is monitored and resolved by a PKCε-regulated pathway.

Brownlow N, Pike T, Zicha D, Collinson L, Parker PJ.

Nat Commun. 2014 Dec 8;5:5685. doi: 10.1038/ncomms6685.

24.

Targeting protein kinase C in sarcoma.

Martin-Liberal J, Cameron AJ, Claus J, Judson IR, Parker PJ, Linch M.

Biochim Biophys Acta. 2014 Dec;1846(2):547-59. doi: 10.1016/j.bbcan.2014.10.002. Epub 2014 Oct 16. Review.

PMID:
25453364
25.

Acute regulation of PDK1 by a complex interplay of molecular switches.

Calleja V, Laguerre M, de Las Heras-Martinez G, Parker PJ, Requejo-Isidro J, Larijani B.

Biochem Soc Trans. 2014 Oct;42(5):1435-40. doi: 10.1042/BST20140222. Review.

PMID:
25233428
26.

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.

Claus J, Patel G, Ng T, Parker PJ.

Biochem Soc Trans. 2014 Aug;42(4):831-6. doi: 10.1042/BST20140043. Review.

PMID:
25109965
27.

Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.

Endesfelder D, Burrell R, Kanu N, McGranahan N, Howell M, Parker PJ, Downward J, Swanton C, Kschischo M.

Cancer Res. 2014 Sep 1;74(17):4853-4863. doi: 10.1158/0008-5472.CAN-13-2664. Epub 2014 Jun 26.

28.

High-throughput time-resolved FRET reveals Akt/PKB activation as a poor prognostic marker in breast cancer.

Veeriah S, Leboucher P, de Naurois J, Jethwa N, Nye E, Bunting T, Stone R, Stamp G, Calleja V, Jeffrey SS, Parker PJ, Larijani B.

Cancer Res. 2014 Sep 15;74(18):4983-95. doi: 10.1158/0008-5472.CAN-13-3382. Epub 2014 Jun 26.

29.

Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways.

Ménard L, Parker PJ, Kermorgant S.

Nat Commun. 2014 May 19;5:3907. doi: 10.1038/ncomms4907.

PMID:
24835487
30.

Control of MT1-MMP transport by atypical PKC during breast-cancer progression.

Rossé C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M, Lagoutte E, Vacher S, Waharte F, Paul-Gilloteaux P, Romao M, Sengmanivong L, Linch M, van Lint J, Raposo G, Vincent-Salomon A, Bièche I, Parker PJ, Chavrier P.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1872-9. doi: 10.1073/pnas.1400749111. Epub 2014 Apr 21.

31.

Functional implications of assigned, assumed and assembled PKC structures.

Linch M, Riou P, Claus J, Cameron AJ, de Naurois J, Larijani B, Ng T, McDonald NQ, Parker PJ.

Biochem Soc Trans. 2014 Feb;42(1):35-41. doi: 10.1042/BST20130192.

PMID:
24450624
32.

Atypical protein kinase Cι as a human oncogene and therapeutic target.

Parker PJ, Justilien V, Riou P, Linch M, Fields AP.

Biochem Pharmacol. 2014 Mar 1;88(1):1-11. doi: 10.1016/j.bcp.2013.10.023. Epub 2013 Nov 11. Review.

33.

The evaluation of an abdominal aortic tourniquet for the control of pelvic and lower limb hemorrhage.

Taylor DM, Coleman M, Parker PJ.

Mil Med. 2013 Nov;178(11):1196-201. doi: 10.7205/MILMED-D-13-00223.

PMID:
24183765
34.

Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.

Linch M, Sanz-Garcia M, Rosse C, Riou P, Peel N, Madsen CD, Sahai E, Downward J, Khwaja A, Dillon C, Roffey J, Cameron AJ, Parker PJ.

Carcinogenesis. 2014 Feb;35(2):396-406. doi: 10.1093/carcin/bgt313. Epub 2013 Sep 26.

35.

A cancer-associated mutation in atypical protein kinase Cι occurs in a substrate-specific recruitment motif.

Linch M, Sanz-Garcia M, Soriano E, Zhang Y, Riou P, Rosse C, Cameron A, Knowles P, Purkiss A, Kjaer S, McDonald NQ, Parker PJ.

Sci Signal. 2013 Sep 17;6(293):ra82. doi: 10.1126/scisignal.2004068.

PMID:
24045153
36.

Pseudokinase drug intervention: a potentially poisoned chalice.

Claus J, Cameron AJ, Parker PJ.

Biochem Soc Trans. 2013 Aug;41(4):1083-8. doi: 10.1042/BST20130078. Review.

PMID:
23863183
37.

14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins.

Riou P, Kjær S, Garg R, Purkiss A, George R, Cain RJ, Bineva G, Reymond N, McColl B, Thompson AJ, O'Reilly N, McDonald NQ, Parker PJ, Ridley AJ.

Cell. 2013 Apr 25;153(3):640-53. doi: 10.1016/j.cell.2013.03.044. Erratum in: Cell. 2013 May 23;153(5):1164.

38.

ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.

Radtke S, Milanovic M, Rossé C, De Rycker M, Lachmann S, Hibbert A, Kermorgant S, Parker PJ.

J Cell Sci. 2013 Jun 1;126(Pt 11):2381-91. doi: 10.1242/jcs.115832. Epub 2013 Apr 2.

39.

Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes.

Kjær S, Linch M, Purkiss A, Kostelecky B, Knowles PP, Rosse C, Riou P, Soudy C, Kaye S, Patel B, Soriano E, Murray-Rust J, Barton C, Dillon C, Roffey J, Parker PJ, McDonald NQ.

Biochem J. 2013 Apr 15;451(2):329-42. doi: 10.1042/BJ20121871.

PMID:
23418854
40.

Localised interventions in cellular processes.

Peel N, Larijani B, Parker PJ.

Biochim Biophys Acta. 2013 Jul;1834(7):1364-70. doi: 10.1016/j.bbapap.2013.01.044. Epub 2013 Feb 9. Review.

PMID:
23403146
41.

Binding of dynein intermediate chain 2 to paxillin controls focal adhesion dynamics and migration.

Rosse C, Boeckeler K, Linch M, Radtke S, Frith D, Barnouin K, Morsi AS, Hafezparast M, Howell M, Parker PJ.

J Cell Sci. 2012 Aug 15;125(Pt 16):3733-8. doi: 10.1242/jcs.089557. Epub 2012 May 2.

42.

Re: An evaluation of two tourniquet systems for the control of prehospital lower limb hemorrhage.

Taylor DM, Parker PJ.

J Trauma Acute Care Surg. 2012 Apr;72(4):1121. doi: 10.1097/TA.0b013e3182423d86. No abstract available.

PMID:
22491645
43.

Changes in surgical workload at the JF Med Gp Role 3 Hospital, Camp Bastion, Afghanistan, November 2008-November 2010.

Jacobs N, Taylor DM, Parker PJ.

Injury. 2012 Jul;43(7):1037-40. doi: 10.1016/j.injury.2011.12.017. Epub 2012 Jan 10.

PMID:
22236366
44.

A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse.

Carlin LM, Evans R, Milewicz H, Fernandes L, Matthews DR, Perani M, Levitt J, Keppler MD, Monypenny J, Coolen T, Barber PR, Vojnovic B, Suhling K, Fraternali F, Ameer-Beg S, Parker PJ, Thomas NS, Ng T.

Sci Signal. 2011 Nov 29;4(201):ra81. doi: 10.1126/scisignal.2001729.

45.

mTORC2 targets AGC kinases through Sin1-dependent recruitment.

Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ.

Biochem J. 2011 Oct 15;439(2):287-97. doi: 10.1042/BJ20110678.

PMID:
21806543
46.

Initial extremity war wound debridement: a multidisciplinary consensus.

Guthrie HC, Clasper JC, Kay AR, Parker PJ; Limb Trauma and Wounds Working Groups, ADMST.

J R Army Med Corps. 2011 Jun;157(2):170-5.

PMID:
21805768
47.

An evaluation of two tourniquet systems for the control of prehospital lower limb hemorrhage.

Taylor DM, Vater GM, Parker PJ.

J Trauma. 2011 Sep;71(3):591-5. doi: 10.1097/TA.0b013e31820e0e41.

PMID:
21768905
48.

Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration.

Lachmann S, Jevons A, De Rycker M, Casamassima A, Radtke S, Collazos A, Parker PJ.

PLoS One. 2011;6(7):e21732. doi: 10.1371/journal.pone.0021732. Epub 2011 Jul 6.

49.

Site recognition and substrate screens for PKN family proteins.

Collazos A, Michael N, Whelan RD, Kelly G, Mellor H, Pang LC, Totty N, Parker PJ.

Biochem J. 2011 Sep 15;438(3):535-43. doi: 10.1042/BJ20110521.

PMID:
21749319
50.

The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A.

Verma SK, Ganesan TS, Kishore U, Parker PJ.

Protein Cell. 2011 Mar;2(3):237-49. doi: 10.1007/s13238-011-1028-z. Epub 2011 Apr 6.

Supplemental Content

Loading ...
Support Center